StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $68.32 | $69.32 | +1.46% | 0.8M |
| 05-12 | $69.32 | $72.07 | +3.97% | 1.6M |
| 05-13 | $71.88 | $74.00 | +2.95% | 0.7M |
| 05-14 | $74.23 | $69.53 | -6.32% | 1.3M |
| 05-15 | $69.20 | $66.93 | -3.28% | 1.2M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $1.08M | $4.04M | $1.72M | $52.00K |
Operating Income | $-66.39M | $-190.77M | $-142.07M | $-90.94M |
Net Income | $-60.20M | $-161.00M | $-119.69M | $-41.43M |
EPS (Diluted) | $-0.71 | $-2.08 | $-1.57 | $-1.00 |
Total Assets | $1.14B | $791.59M | $729.91M | $701.45M |
Total Liabilities | $43.48M | $38.99M | $42.27M | $31.09M |
Cash & Equivalents | $33.70M | $32.49M | $45.15M | $14.62M |
Free Cash Flow OCF − CapEx | $-57.25M | $-132.48M | $-96.26M | $-57.27M |
Shares Outstanding | 88.01M | 80.69M | 78.28M | 76.23M |
No sell-side coverage available for CGON.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for CGON.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.